The first strategy employed when designing CRAds is to replace the E1 promotor with a tumour specific promotor, therefore preventing induction of E1A mediated viral replication in the absence of the appropriate promoter [86,87,88]. This evidence concerns the gene DHTKD1 and neoplasm.